

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA ISOTOPE & RADIATION CORPORATION**

**中國同輻股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1763)**

### **VOLUNTARY ANNOUNCEMENT CHINA ISOTOPE ASSISTING THE ESTABLISHMENT OF XINJIANG “BELT AND ROAD” NUCLEAR MEDICINE DEVELOPMENT COMMITTEE**

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, the Company actively promoted the Xinjiang Uygur Autonomous Region People’s Hospital, the Affiliated Tumor Hospital of Xinjiang Medical University and other major hospitals and experts to jointly establish the Xinjiang “Belt and Road” Nuclear Medicine Development Committee.

The establishment of the Xinjiang “Belt and Road” Nuclear Medicine Development Committee aims to promote the high-quality construction of nuclear medicine department in Xinjiang. Through the platform of Xinjiang “Belt and Road” Nuclear Medicine Development Committee, the Company actively promotes the integration of nuclear medicine industry resources in hospitals, provides integrated intelligent nuclear medicine turnkey services for newly built and to-be-built hospitals, and promotes the standardized and high-quality development of nuclear medicine department and clinical precision diagnosis and treatment in Xinjiang.

The Company has reached a strategic cooperation with the Nuclear Medicine Branch of the Chinese Medical Association. In the nuclear medicine diagnosis and treatment promotion demonstration base construction project, they will leverage their respective resource advantages in expert guidance, talent training, drug release research and development, and department construction to jointly help the implementation of the Xinjiang “Belt and Road” Nuclear Medicine Development Committee.

Xinjiang Uygur Autonomous Region People's Hospital, being the chairman unit of the Nuclear Medicine Professional Committee of Xinjiang Medical Association and also the most influential general hospital in Xinjiang, has played an active role in the development of Xinjiang's nuclear medicine industry. The Company has reached a strategic cooperation with the Xinjiang Uygur Autonomous Region People's Hospital. The two parties will cooperate in depth to jointly build a demonstration base for integrated diagnosis and treatment of intelligent nuclear medicine, establish a five-in-one intelligent nuclear medicine department, establish standardized, normalized and intelligent guidelines in department quality control, build a model project for the high-quality development of nuclear medicine department, and play a positive role in the future development of nuclear medicine in Xinjiang.

By order of the Board  
**China Isotope & Radiation Corporation**  
**Wang Suohui**  
*Chairman*

Beijing, the PRC, 18 July 2023

*As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.*